Putting the ‘HAT’ back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions

Author： Sleiman Sama F   Basso Manuela   Mahishi Lata   Kozikowski Alan P   Donohoe Mary E   Langley Brett   Ratan Rajiv R  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.18, Iss.5, 2009-05, pp. : 573-584

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?

By Burnett John R   Watts Gerald F  

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 2, 2007-02 ,pp. : 181-189

Informa Healthcare

Access to resources Recommend Favorite

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

By Lenz Johannes Carl Christoph   Rockstroh Jüürgen Kurt  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 537-548

Informa Healthcare

Access to resources Recommend Favorite

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

By  

Current Cancer Drug Targets, Vol. 12, Iss. 7, 2012-09 ,pp. : 838-846

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy

By  

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 61-70

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy

By  

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 61-70

Bentham Science Publishers

Access to resources Recommend Favorite